SI-BONE Reports Third-Quarter Revenue of $55.7 Million, Cuts Expense Growth Outlook
SI-BONE reported third-quarter 2026 revenue of $55.7 million, net loss of $3.6 million, or $0.08 per diluted share, and adjusted EBITDA of $3.0 million. It reaffirmed 2026 worldwide revenue and gross margin guidance while lowering expected operating expense growth to 10.5%.
SI-BONE, Inc. reported third-quarter 2026 revenue of $55.7 million, surpassing the FactSet consensus estimate of $55.3 million. The company's net loss improved to $3.6 million, or $0.08 per diluted share, compared to a net loss of $4.6 million, or $0.11 per diluted share, in the same period of 2025. Adjusted EBITDA rose to $3.0 million from $2.3 million in the corresponding 2025 period.
Management reaffirmed the company's previously issued 2026 worldwide revenue and gross margin guidance while announcing a reduction in the expected operating expense growth rate to 10.5%. CEO Laura Francis attributed the results to robust growth in procedure volumes and active physician engagement.